Literature DB >> 16457782

The role of CREB in depression and antidepressant treatment.

Julie A Blendy1.   

Abstract

Major depressive disorder is a severe clinical problem across the globe, with a lifetime risk of 10%-30% for women and 7%-15% for men. The World Health Organization ranks major depression at the top of the list in terms of disease burden, and this burden is expected to rise in the next decade as the prevalence of the disorder grows. Since the late 1950s, a wide range of antidepressant medications targeting the monoamine systems has been available to alleviate the symptoms of major depressive disorder. Although widely prescribed, such antidepressant medications are accompanied by a delay in effectiveness, as well as varied side effects. Therefore, further characterization of the biological mechanisms behind their function is crucial for the development of new and more effective treatments. One protein that could serve as a convergence point for multiple classes of antidepressant drugs is the transcription factor CREB (cyclic adenosine monophosphate response element binding protein). CREB is upregulated by chronic antidepressant treatment, and increasing CREB levels in rodent models results in antidepressant-like behaviors. Furthermore, postmortem studies indicate that CREB levels are increased in subjects taking antidepressants at the time of death. However, not all antidepressants increase CREB levels and/or activity, and reducing CREB levels in some brain regions also results in antidepressant-like behaviors. This review attempts to consolidate the information relevant to the structure and function of the CREB protein and describe how this relates to the mechanism of antidepressant drugs. Animal models in which CREB function is enhanced, by overexpression of the protein, or reduced, by expression of mutant forms of the protein or through gene deletion experiments, are summarized in terms of identifying a role for CREB in behavioral responses in depression tests that were originally designed to evaluate antidepressant efficacy. Human postmortem and genetic studies that implicate CREB in depression and antidepressant efficacy are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16457782     DOI: 10.1016/j.biopsych.2005.11.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  119 in total

1.  Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression.

Authors:  Bhavya Voleti; Keith Q Tanis; Samuel S Newton; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2011-09-19       Impact factor: 13.382

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  α₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims.

Authors:  Elsa M Valdizán; Rebeca Díez-Alarcia; Javier González-Maeso; Fuencisla Pilar-Cuéllar; Jesús A García-Sevilla; J Javier Meana; Angel Pazos
Journal:  Biol Psychiatry       Date:  2010-09-22       Impact factor: 13.382

4.  Serum response factor and cAMP response element binding protein are both required for cocaine induction of ΔFosB.

Authors:  Vincent Vialou; Jian Feng; Alfred J Robison; Stacy M Ku; Deveroux Ferguson; Kimberly N Scobie; Michelle S Mazei-Robison; Ezekiell Mouzon; Eric J Nestler
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 5.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

6.  Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor.

Authors:  Seiko Yasuda; Mitsuhiro Yoshida; Hirotaka Yamagata; Yasutake Iwanaga; Hiromi Suenaga; Kozo Ishikawa; Masako Nakano; Satoshi Okuyama; Yoshiko Furukawa; Shoei Furukawa; Toshizo Ishikawa
Journal:  Cell Mol Neurobiol       Date:  2014-08-26       Impact factor: 5.046

Review 7.  A model for streamlining psychotherapy in the RDoC era: the example of 'Engage'.

Authors:  G S Alexopoulos; P Arean
Journal:  Mol Psychiatry       Date:  2013-11-26       Impact factor: 15.992

8.  Transcriptomic predictors of inflammation-induced depressed mood.

Authors:  Joshua Hyong-Jin Cho; Michael R Irwin; Naomi I Eisenberger; Donald M Lamkin; Steve W Cole
Journal:  Neuropsychopharmacology       Date:  2019-01-14       Impact factor: 7.853

9.  Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice.

Authors:  Lu Song; Hao Wang; Ying-Jie Wang; Jin-Liang Wang; Qing Zhu; Feng Wu; Wei Zhang; Bo Jiang
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

10.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.